H pylori infection may diminish immunotherapy response in Acute gastric cancer patients

Results:

A total of 77 patients were included in this study; 34 patients were H. pylori-positive, and the prevalence of H. pylori infection was 44.2%. Compared with the H. pylori-negative group, patients in the H. pylori-positive group had a higher risk of nonclinical response to anti-PD-1 antibody, with an OR of 2.91 (95% CI: 1.13-7.50). Patients in the H. pylori-negative group had a longer OS and PFS than those in the positive group, with an estimated median OS of 17.5 months vs. 6.2 months (HR = 2.85, 95% CI: 1.70-4.78; P = 0.021) and a median PFS of 8.4 months vs. 2.7 months (HR=3.11, 95% CI: 1.96-5.07, P=0.008). Multivariate analysis indicated that H. pylori infection was independently associated with PFS (HR=1.90, 95% CI: 1.10-3.30; P=0.022).

Thus, the study unveils for the first time that H. pylori infection is associated with the outcome of immunotherapy for advanced gastric cancer patients. A multicenter, large sample and prospective clinical studies are needed to verify the association.

Reference:

Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors by Hebin Che, et al. published in the Research Square

https://doi.org/10.21203/rs.3.rs-1590446/v1